ProfileGDS5678 / 1430959_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 51% 45% 44% 44% 55% 43% 45% 42% 43% 43% 46% 48% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0736444
GSM967853U87-EV human glioblastoma xenograft - Control 23.2139551
GSM967854U87-EV human glioblastoma xenograft - Control 33.0389545
GSM967855U87-EV human glioblastoma xenograft - Control 42.9746244
GSM967856U87-EV human glioblastoma xenograft - Control 52.9751844
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4752755
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.06643
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0526445
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9557242
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9825543
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9811343
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0317146
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1444448
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9995343